Digital CBT versus nightly trazodone versus nightly daridorexant for menopause-related insomnia
Official title: CELESTE: Comparative Effectiveness Study of behavioraL and Drug-rElated inSomnia Therapies for pEri- and Post-menopausal People
Run by Brigham and Women's Hospital · NCT07136415 · Data updated 2026-11-12
This project will see if online cognitive behavioral therapy, nightly trazodone, or nightly daridorexant helps people in peri- and post-menopause who are having insomnia.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 40 Years to 62 Years |
| Sex | Women only |
| Enrollment | 1000 (estimated) |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Locations | 5 sites (Boston, Massachusetts and 4 other locations) |
| Status | Recruiting |
| Started | February 13, 2026 |
| Main results expected | February 2031 |
| Study ends | February 2031 |
| Registry record updated | June 8, 2026 |
| Trial ID | NCT07136415 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people assigned female at birth aged 40–62 who are in peri- or early post-menopause, have an Insomnia Severity Index >10 with insomnia that started or worsened during menopause, and can complete English- or Spanish-language study procedures.
✕Probably not a fit
People with untreated moderate-to-severe sleep apnea or restless legs syndrome, very high daytime sleepiness (Epworth >15), or other untreated sleep disorders or scheduling barriers are unlikely to be suitable or to receive benefit from the interventions in this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional Phase 4 comparative study assigns participants to one of three common insomnia treatments—digital CBT for insomnia, nightly trazodone, or nightly daridorexant—and follows them for about 12 months. Participants complete one in-person baseline visit (including surveys, urine pregnancy test, ECG, and height/weight) and seven virtual follow-up visits, wear a Fitbit around baseline, and keep sleep diaries. The trial focuses on people assigned female at birth aged about 40–62 in peri- or early post-menopause whose insomnia began or worsened during the menopausal transition, and it collects data on symptom change and safety events. The study also examines how treatment effects vary by background, menopausal stage, and common coexisting conditions such as sleep apnea or mood disturbance.
Why it matters
Potential benefit: If successful, the results could clarify which of these three options best improves sleep and safety for peri- and post-menopausal people, helping clinicians choose the most effective treatment.
How similar studies have gone: Cognitive behavioral therapy for insomnia is well-supported by evidence and daridorexant is an FDA-approved effective insomnia medicine, while trazodone is commonly used off-label for sleep but has less rigorous comparative data in menopausal populations, so direct head-to-head evidence in this group is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 40-62 years * Assigned female sex at birth * In peri- or early menopause, following the STRAW criteria of self-report of irregular menstrual cycle or within 5 years from the last menstrual period. When menstrual markers are absent or unreliable (e.g., hysterectomy; endometrial ablation), participants must be older than 45 years old and report hot flashes * Insomnia severity index score \> 10 at screening * Insomnia started or worsened during peri- or early menopause * English or Spanish speaking (Spanish-only speaking individuals will be recruited after full development of Spanish-facing materials, which may lag initial study start) Exclusion Criteria: * Untreated, previously diagnosed severe sleep apnea (self-report; chart review; clinician assessment) * Untreated, previously diagnosed moderate-severe restless legs syndrome (self-report; chart review) * Severe daytime sleepiness (Epworth Sleepiness Scale \> 15) at screening * Sleep schedule issues that would impact effectiveness of the interventions (e.g., night shift workers with \>1 night shift/week; main sleep period outside of 8pm - 11am) * Regular use of hypnotics \> 2 nights/week * Limited internet access * Pregnant or lactating or positive urine pregnancy test at baseline visit * Prolonged QTc interval (\>460 ms) (by study baseline electrocardiogram (EKG) or EKG report in medical record) * History of the following health conditions: Uncontrolled hypertension; clinically significant heart disease such as arrhythmias requiring medication, cardiomyopathies, heart failure, clinically significant valvular heart disease, or severe coronary artery disease (unstable angina, myocardial infarction in the prior 6 months); hypersomnia or narcolepsy; bipolar disorder, severe depression, or psychosis ; seizure within the past year; use of opioids or substance use disorder; known allergy or contraindication to trazodone or daridorexant (self-report and chart review); known severe chronic liver disease (e.g. cirrhosis); end-stage renal disease on hemodialysis; other severe medical comorbidity (e.g. likely hospitalization within next 6 months or medical conditions that increase risk of participation at a study clinician's discretion) * Use of medications such as those that: Have known potential for significantly prolonging the QT interval (i.e. antiarrhythmics such as amiodarone, sotalol, quinidine, procainamide, dofetilide, and ibutilide), are strong CYP3A4 inhibitors, or are moderate or strong CYP3A4 inducers * Use of one of the interventions in the past 6 months * Other conditions determined by the PI or study clinician to preclude study participation
Where it's running
-
Brigham and Women's Hospital
Boston, Massachusetts, United States Recruiting -
Henry Ford Medical Center
Novi, Michigan, United States Recruiting -
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States Recruiting -
University of Utah
Salt Lake City, Utah, United States Recruiting -
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States Not yet recruiting
Study contacts
- Principal investigator: Suzanne Bertisch, MD, MPH — Brigham and Women's Hospital
- Study coordinator: Sharon Ng, MS
- Email: shng1@mgh.harvard.edu
- Phone: 617-525-7097
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SleepCogni for children with chronic insomnia
A handheld SleepCogni device is tested to see if it helps kids aged 6–16 with chronic insomnia sleep better.
-
Music therapy after stroke
This trial tests whether adding music therapy to standard care helps stroke patients sleep better and feel less anxious or depressed while in the hospital.
-
Remote ischemic conditioning for post-stroke insomnia
A 136-person, randomized study will test whether a non-invasive arm-cuff procedure done twice daily for 90 days can improve sleep after a first ischemic stroke in adults 18–80.
-
Nurse-guided app-based brief behavioral therapy for insomnia in older adults
Aging adults with insomnia will be asked to try a nurse-supported, smartphone app therapy for four weeks to see if it helps with sleep.
-
Three rTMS approaches to lessen insomnia-related pain after exercise-induced muscle soreness
This study tests whether three different rTMS approaches can reduce pain sensitivity and improve recovery in adults with insomnia after inducing muscle soreness from exercise.
-
Insomnia and Sleep Disruption's Effect on Pain Sensitivity and Muscle Soreness After Exercise
This study tests whether poor sleep or insomnia affects how people feel pain and recover from exercise-induced muscle soreness in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.